



Meeting with EMA: cooperation in the field of ERNs

Enrique Terol DG SANTE European Commission

**London 16 May 2017** 

# The road to European Reference Networks (ERNs)

Imagine if the best specialists from across Europe could join their efforts to tackle complex or rare medical conditions that require highly specialized healthcare and a concentration of knowledge and resources.













**Chapter IV Cooperation between MS Article 12 European Reference Networks** 

Networks of healthcare providers aiming at improving quality, and safety and access to highly specialised healthcare

Commission

Patients affected by rare or low prevalence and complex diseases

Added value at EU level

Multidisciplinary approach (different specialities/areas of knowledge)

#### Need of cooperation:

- Scarcity knowledge
- Need education
- Complexity / high cost
- Effectiveness in the use of resources

"The knowledge travels, not the patient"





## **Common ERN objectives**

To ensure that ERNs are operational

To improve access to clinical advise, diagnosis, treatment and follow-up of patients

To optimise patient outcomes by combining expertise

To promote education and training

To reinforce clinical research

To ensure access to high quality healthcare services


To guarantee that knowledge is spread outside the ERN



## Share. Care. Cure.







Clinical virtual care

Remote monitoring & follow-up

Remote guidance and diagnosis

Health and Food Safety

## **Outcome call 2016**





24



European Reference Networks



**Networks** 

**26 COUNTRIES** 



> 300 HOSPITALS

Full Member

Affiliated partner (late 2017 ?)











**(24)** 



BOND ERN	Bone Diseases
CRANIO	Craniofacial anomalies and ENT disorders
Endo-ERN	Endocrine Conditions
EpiCARE	Rare and Complex Epilepsies
ERKNet	Kidney Diseases
ERN GENTURIS	Genetic Tumour Risk Syndromes
ERN-EYE	Eye Diseases
ERNICA	inherited and congenital anomalies
ERN-LUNG	Respiratory Diseases
ERN-RND	Neurological Diseases
ERN-Skin	Skin Disorders
EURACAN	Solid Adult Cancers

EuroBloodNet	Onco-Hematological Diseases
EUROGEN EURO-NMD	Urogenital Diseases Neuromuscular Diseases
GUARD-HEART	Diseases of the Heart
ITHACA	Congenital Malformations and Intellectual Disability
MetabERN	Hereditary metabolic diseases
PaedCan-ERN	Paediatric Cancer
RARE-LIVER	Hepatological Diseases
ReCONNET	Connective Tissue and Musculoskeletal Diseases
RITA	Immunodeficiency, AutoInflammatory and Auto Immune Diseases
TRANSPLANT-CHILD	Transplantation in Children
VASCERN	Multisystemic Vascular Diseases

European Commission





# Research, innovation & knowledge generation Key Elements of ERNs

- ➤ A framework for structured cooperation to maximise cross-country expertise through joint research projects and clinical trials
- ➤ ERN provide an <u>Opportunity</u> to build top level translational and basic research around shared strategies
- Dissemination of research results, education & training activities

#### Research and ERNs





PATIENT CARE
Patient clinical unmeet
needs
(treatment/diagnosis)



RESEARCH
Research question/gap
Prospective/translational
research
Clinical trials

#### Patient Data

Population Cohorts/Concentration of cases
Secured Databases
Clinical/Imaging/ Biological Data
Genetics, Molecular Pathology
IT Solutions / Communication between HCP

common elements , principles and requisites



# Phases of the ERN life cycle





We are hera

2011-14

Legislation and initial planning

Directive

Implementing decisions

Awareness and communication

project cycle re-initiation

2015-16

**Implementation:** (Approval stage)

Design and development Assessment tools

Call for ERN

Assessment of Network proposals

Approval of ERNs

2021

Evaluation and update

2017-18

Implementation: (deployment stage)

Establishment

Initial organizational phase

Functioning (initial actions and services)

Partial service production

2019-20

Consolidation

Full service production

Continuous monitoring

Performance indicators and initial outcome assessment

Health and Food Safety




**ERNs** 

**BoMS** 



### Actors involved in the ERN implementation



Commission expert group on rare diseases







National Healthcare System





Patients organisations











## **ERN Board of MS**

Affiliated partners



> ERN & Industry



ERN IT platform



ERN monitoring and assessment system (June 2017)



Link national networks/highly specialised centres to ERNs



Support to Network coordinators and members of the ERN







## **ERN Coordinators Group (ERN-CG)**

### Network of the Networks body

- Set up 8.10 March
- Meetings: 26-27 April; 20 June; 30 October

#### Governance model

### Priorities & work plan 2017-18

- Transversal & technical issues
- Crosslink
- Set-up working groups , goals and deliverables







## ERN's IT Platform and tools (under development)



CLINICAL Online patient management

> July 2017

Web/video conferencing, Virtual clinical meetings

Exchange of Images (Radiology), diagnostic tests & pictures (genetics, pathology etc., (PACS)

**Exchange of clinical information and patient data** 

Communication and collaboration

March 2017 Management /governance tools

**Communication/conferencing tools** 

Health and Food Safety





## **Funding/support**



THE THIRD HEALTH PROGRAMME 2014-2020 FUNDING HEALTH INITIATIVES









EUROPEAN UNION STRUCTURAL FUNDS









# EMA and ERNs: cooperation based on mutual benefits











### Common areas of interest / action

- Approval of <u>new drugs</u> for the benefit of patients
- Strong <u>innovation</u> dimension
- <u>Knowledge generation</u> (Clinical guidelines, evidence etc..)
- Low prevalence and complex diseases (<u>Orphan</u> drugs)
- Advanced therapies: Genetic origin of diseases:
- Scientific and expert <u>advise</u>
- Interaction between research, clinical care and healthcare provision organisation







## Capacities of the ERNs

- Sustainable and robust structure
- Scientific and clinical expertise ("best in class")
- Data collection capacity (IT clinical platform)
- Commercial & non commercial clinical trials

- Long term follow up
- EU cohorts of patients
- Post-commercial studies:
  - ✓ Off label use of medicines
  - ✓ Repurposing
  - ✓ Compassionate use
- Patient safety / adverse events analysis and reporting





# Common challenges

- Ethical concerns
- Data management/protection/ownership
- Information to patients
- Patient registries strategy
- Standards in clinical practice and clinical guidelines development










# 5 year planning

- ➤ Integration of policies
- > Funding
- > Tools
- ➤ Member States role
- Network outcomes

# European Reference Networks: Project implementation





# **Challenges**



Commission



#### **General Framework**

- ✓ Definition of the <u>legal status of ERNs</u>
- Referral of patients (Social Security and CBHC Directive)
- ✓ ERNs & national healthcare systems

  Integration
- ✓ Liability & Data protection
- ✓ ERN IT solutions
- ✓ Coordination <u>relevant funding</u> streams
- ✓ <u>UK HCPs in a post-Brexit</u> scenario
- ✓ Sustainability of ERNs and opportunities for continued funding post-2022

#### **Specific tasks of ERNs**

- ✓ ERN management (coordinators)
- ✓ Clinical virtual care
- Coordination within the Network
- ✓ Knowledge generation & dissemination
- Development of patient pathways& shared clinical guidelines
- ✓ ERN crosslink
- Clinical outcomes
- ✓ Research leadership







#### **Further**

information: http://ec.europa.eu/health/ern/toolkit\_en



http://ec.europa.eu/health/ern/policy/index\_en.htm

Enrique.terol@ec.europa.eu



